Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 178

1.

Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan.

Metz R, Duhadaway JB, Kamasani U, Laury-Kleintop L, Muller AJ, Prendergast GC.

Cancer Res. 2007 Aug 1;67(15):7082-7.

2.

IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism.

Löb S, Königsrainer A, Zieker D, Brücher BL, Rammensee HG, Opelz G, Terness P.

Cancer Immunol Immunother. 2009 Jan;58(1):153-7. doi: 10.1007/s00262-008-0513-6. Epub 2008 Apr 17.

PMID:
18418598
3.

Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway.

Ball HJ, Yuasa HJ, Austin CJ, Weiser S, Hunt NH.

Int J Biochem Cell Biol. 2009 Mar;41(3):467-71. doi: 10.1016/j.biocel.2008.01.005. Epub 2008 Jan 11. Review.

PMID:
18282734
4.

Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells.

Lob S, Konigsrainer A, Schafer R, Rammensee HG, Opelz G, Terness P.

Blood. 2008 Feb 15;111(4):2152-4. Epub 2007 Nov 28.

5.

Biochemical characteristics and inhibitor selectivity of mouse indoleamine 2,3-dioxygenase-2.

Austin CJ, Mailu BM, Maghzal GJ, Sanchez-Perez A, Rahlfs S, Zocher K, Yuasa HJ, Arthur JW, Becker K, Stocker R, Hunt NH, Ball HJ.

Amino Acids. 2010 Jul;39(2):565-78. doi: 10.1007/s00726-010-0475-9. Epub 2010 Feb 7.

PMID:
20140689
6.

Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.

Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, Mellor AL, Prendergast GC, Munn DH.

Cancer Res. 2007 Jan 15;67(2):792-801.

7.

Effects of 1-methyltryptophan stereoisomers on IDO2 enzyme activity and IDO2-mediated arrest of human T cell proliferation.

Qian F, Liao J, Villella J, Edwards R, Kalinski P, Lele S, Shrikant P, Odunsi K.

Cancer Immunol Immunother. 2012 Nov;61(11):2013-20. doi: 10.1007/s00262-012-1265-x. Epub 2012 Apr 22.

PMID:
22527253
8.

Expression of indoleamine 2,3-dioxygenase in acute myeloid leukemia and the effect of its inhibition on cultured leukemia blast cells.

El Kholy NM, Sallam MM, Ahmed MB, Sallam RM, Asfour IA, Hammouda JA, Habib HZ, Abu-Zahra F.

Med Oncol. 2011 Mar;28(1):270-8. doi: 10.1007/s12032-010-9459-6. Epub 2010 Mar 19.

PMID:
20300979
9.

Novel 1-alkyl-tryptophan derivatives downregulate IDO1 and IDO2 mRNA expression induced by interferon-gamma in dendritic cells.

Sun T, Chen XH, Tang ZD, Cai J, Wang XY, Wang SC, Li ZL.

Mol Cell Biochem. 2010 Sep;342(1-2):29-34. doi: 10.1007/s11010-010-0465-y. Epub 2010 Apr 28.

PMID:
20424892
10.

1-L-methyltryptophan is a more effective inhibitor of vertebrate IDO2 enzymes than 1-D-methyltryptophan.

Yuasa HJ, Ball HJ, Austin CJ, Hunt NH.

Comp Biochem Physiol B Biochem Mol Biol. 2010 Sep;157(1):10-5. doi: 10.1016/j.cbpb.2010.04.006. Epub 2010 Apr 23.

PMID:
20399882
11.

Human indoleamine 2,3-dioxygenase-2 has substrate specificity and inhibition characteristics distinct from those of indoleamine 2,3-dioxygenase-1.

Pantouris G, Serys M, Yuasa HJ, Ball HJ, Mowat CG.

Amino Acids. 2014 Sep;46(9):2155-63. doi: 10.1007/s00726-014-1766-3. Epub 2014 May 30.

PMID:
24875753
12.

Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer.

Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario JD Jr, Andrews C, Matsuzaki J, Valmori D, Ayyoub M, Frederick PJ, Beck A, Liao J, Cheney R, Moysich K, Lele S, Shrikant P, Old LJ, Odunsi K.

Cancer Res. 2009 Jul 1;69(13):5498-504. doi: 10.1158/0008-5472.CAN-08-2106. Epub 2009 Jun 2.

13.
14.

Inhibition of indoleamine 2,3-dioxygenase suppresses NK cell activity and accelerates tumor growth.

Kai S, Goto S, Tahara K, Sasaki A, Kawano K, Kitano S.

J Exp Ther Oncol. 2003 Nov-Dec;3(6):336-45.

PMID:
14678522
15.

Indoleamine 2,3-dioxygenase: is it an immune suppressor?

Soliman H, Mediavilla-Varela M, Antonia S.

Cancer J. 2010 Jul-Aug;16(4):354-9. doi: 10.1097/PPO.0b013e3181eb3343. Review.

16.

Spontaneous cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2.

Sørensen RB, Køllgaard T, Andersen RS, van den Berg JH, Svane IM, Straten Pt, Andersen MH.

Cancer Res. 2011 Mar 15;71(6):2038-44. doi: 10.1158/0008-5472.CAN-10-3403.

17.

Indoleamine 2,3-dioxygenase as a new target for malignant glioma therapy. Laboratory investigation.

Miyazaki T, Moritake K, Yamada K, Hara N, Osago H, Shibata T, Akiyama Y, Tsuchiya M.

J Neurosurg. 2009 Aug;111(2):230-7. doi: 10.3171/2008.10.JNS081141.

PMID:
19199463
18.

Characterization and evolution of vertebrate indoleamine 2, 3-dioxygenases IDOs from monotremes and marsupials.

Yuasa HJ, Ball HJ, Ho YF, Austin CJ, Whittington CM, Belov K, Maghzal GJ, Jermiin LS, Hunt NH.

Comp Biochem Physiol B Biochem Mol Biol. 2009 Jun;153(2):137-44.

PMID:
19402226
19.

Indoleamine 2,3-dioxygenase 2 (IDO2) and the kynurenine pathway: characteristics and potential roles in health and disease.

Fatokun AA, Hunt NH, Ball HJ.

Amino Acids. 2013 Dec;45(6):1319-29. doi: 10.1007/s00726-013-1602-1. Epub 2013 Oct 9. Review.

PMID:
24105077
20.

Supplemental Content

Support Center